Veradigm vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare data company with 130K connected physicians; EHR-connected real-world evidence network for pharma analytics rebranded from Allscripts competing with IQVIA for life sciences data.
About
Veradigm (formerly Allscripts Healthcare) is a healthcare information technology company providing EHR-connected data network services, physician practice management software, pharmacy solutions, and life sciences data analytics — operating at the intersection of clinical care delivery and healthcare data commercialization. Listed on NASDAQ (NASDAQ: MDRX) and headquartered in Chicago, Illinois, Veradigm rebranded from Allscripts in 2023 as it refocused from clinical EHR software toward data and analytics services, generating approximately $600 million in annual revenue.\n\nVeradigm's core asset is its network of approximately 130,000 connected physicians and tens of millions of de-identified patient records accessible through its data products. The Veradigm Network connects ambulatory physician practices running Allscripts EHR (Professional EHR, TouchWorks) and enables data flows for prescription analytics, clinical decision support, and real-world evidence (RWE) for pharmaceutical companies. The life sciences data business provides pharma clients with prescription analytics, patient journey data, and clinical research data services.\n\nIn 2025, Veradigm is in strategic transition — the company has been exploring alternatives to maximize shareholder value, including potential sale or acquisition, following activist investor pressure. The EHR product portfolio (Allscripts-branded physician practice software) competes with athenahealth, Epic, and eClinicalWorks in the ambulatory market, though Veradigm's focus has shifted toward its data network value rather than competing head-to-head in EHR functionality. Veradigm competes with IQVIA, Komodo Health, and Definitive Healthcare for life sciences real-world data. The 2025 strategy focuses on growing the data analytics and real-world evidence business while managing the legacy EHR product base.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.